Table 5.
Comparison of ORR in Subgroups Divided by Baseline Characteristics
| Parameters | N | Not ORR | ORR | p Value |
|---|---|---|---|---|
| Age | 0.368 | |||
| ≥65 years | 121 | 28 (23.1) | 93 (76.9) | |
| <65 years | 246 | 47 (19.1) | 199 (80.9) | |
| Gender | 0.863 | |||
| Male | 286 | 59 (20.6) | 227 (79.4) | |
| Female | 81 | 16 (19.8) | 65 (80.2) | |
| History of HB | 0.001 | |||
| Yes | 244 | 38 (15.6) | 206 (84.4) | |
| No | 123 | 37 (30.1) | 86 (69.9) | |
| History of HC | 0.981 | |||
| Yes | 5 | 1 (20.0) | 4 (80.0) | |
| No | 362 | 74 (20.4) | 288 (79.6) | |
| History of drink | 0.649 | |||
| Yes | 153 | 33 (21.6) | 120 (78.4) | |
| No | 214 | 42 (19.6) | 172 (80.4) | |
| History of cirrhosis | 0.071 | |||
| Yes | 176 | 29 (16.5) | 147 (83.5) | |
| No | 191 | 145 (75.9) | 46 (24.1) | |
| Histology | 0.004 | |||
| Primary HCC | 275 | 45 (16.4) | 230 (83.6) | |
| Primary ICC | 37 | 12 (32.4) | 25 (67.6) | |
| Secondary liver cancer | 55 | 18 (32.7) | 37 (67.3) | |
| Tumor distribution | 0.005 | |||
| Multifocal | 244 | 60 (24.6) | 184 (75.4) | |
| Unifocal | 123 | 15 (12.2) | 108 (87.8) | |
| Tumor location | 0.267 | |||
| Left liver | 56 | 11 (19.6) | 45 (80.4) | |
| Right liver | 183 | 32 (17.5) | 151 (82.5) | |
| Bilobar | 128 | 32 (25.0) | 96 (75.0) | |
| Largest nodule size | 0.918 | |||
| ≥5 cm | 184 | 38 (20.7) | 146 (79.3) | |
| <5 cm | 183 | 37 (20.2) | 146 (79.8) | |
| Portal vein invasion | 0.010 | |||
| Yes | 103 | 30 (29.1) | 73 (70.9) | |
| No | 264 | 45 (17.0) | 219 (83.0) | |
| Hepatic vein invasion | 0.221 | |||
| Yes | 48 | 13 (27.1) | 35 (72.9) | |
| No | 319 | 62 (19.4) | 257 (80.6) | |
| ECOG performance status | 0.489 | |||
| 0 | 200 | 40 (20.0) | 160 (80.0) | |
| 1 | 127 | 25 (19.7) | 102 (80.3) | |
| 2 | 30 | 6 (20.0) | 24 (80.0) | |
| 3 | 10 | 4 (40.0) | 6 (60.0) | |
| Child–Pugh Stage | 0.087 | |||
| A | 261 | 47 (18.0) | 214 (82.0) | |
| B | 49 | 10 (20.4) | 39 (79.6) | |
| C | 2 | 0 (0.0) | 2 (100.0) | |
| BCLC Stage | 0.173 | |||
| 0 | 1 | 0 (0.0) | 1 (100.0) | |
| A | 76 | 12 (15.8) | 64 (84.2) | |
| B | 119 | 20 (16.8) | 99 (83.2) | |
| C | 115 | 25 (21.7) | 90 (78.3) | |
| D | 1 | 0 (0.0) | 1 (100.0) | |
| Cycles of DEB-TACE treatment | 0.356 | |||
| 1 cycle | 305 | 65 (21.3) | 240 (78.7) | |
| 2 or more cycles | 62 | 10 (16.1) | 52 (83.9) | |
| Previous cTACE treatment | 0.069 | |||
| Yes | 138 | 35 (25.4) | 103 (74.6) | |
| No | 229 | 40 (17.5) | 189 (82.5) | |
| Previous surgery | 0.181 | |||
| Yes | 109 | 27 (24.8) | 82 (75.2) | |
| No | 258 | 48 (18.6) | 210 (81.4) | |
| Previous systematic chemotherapy | 0.010 | |||
| Yes | 46 | 16 (34.8) | 30 (65.2) | |
| No | 321 | 59 (18.4) | 262 (81.6) | |
| Previous radiofrequency ablation | 0.424 | |||
| Yes | 53 | 13 (24.5) | 40 (75.5) | |
| No | 314 | 62 (19.7) | 252 (80.3) | |
| Previous targeted therapy | 0.074 | |||
| Yes | 12 | 0 (0.0) | 12 (100.0) | |
| No | 355 | 75 (21.1) | 280 (78.9) | |
| DEBs size | 0.101 | |||
| 100–300 μm | 354 | 70 (19.8) | 284 (80.2) | |
| 300–500 μm | 13 | 5 (38.5) | 8 (61.5) | |
| Drug dosage | 0.360 | |||
| Low dose | 34 | 9 (26.5) | 25 (73.5) | |
| Normal dose | 333 | 66 (19.8) | 267 (80.2) | |
| Combination of ordinary embolization agent | 0.190 | |||
| Yes | 116 | 19 (16.4) | 97 (83.6) | |
| No | 251 | 56 (22.3) | 195 (77.7) |
Data are presented as count with percentage in parentheses. Comparison between two groups was determined by chi-square test. A value of p < 0.05 was considered significant (bold). ORR, objective response rate.